BRIEF — Global offering next in Acacia's mission to become leading hospital-focused pharma group

Acacia Pharma, which is focused on the development and commercialization of new products to treat and prevent nausea and vomiting suffered by surgical and cancer patients, is planning to raise new funds through an Initial Global Offering with admission of all of its ordinary shares to trading on Euronext Brussels.

The UK-based company says it has identified important and commercially attractive unmet needs in nausea and vomiting and has discovered two product candidates to meet those needs. These include Baremsis (amisulpride injection), which is under US Food and Drug Administration review after four positive Phase III trials.

Funds from the global offer will support Acacia’s commercialization plans for Baremsis through establishing a direct hospital salesforce in the USA, and enable the company to begin to advance the development of its second product, APD403.